Detalhe da pesquisa
1.
Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial.
Hum Vaccin Immunother
; 18(6): 2092363, 2022 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35834812
2.
Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial.
Lancet Infect Dis
; 22(12): 1756-1768, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36037823
3.
Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response.
Emerg Microbes Infect
; 10(1): 365-375, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33583360
4.
Immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine under different vaccination intervals.
Hum Vaccin Immunother
; 16(7): 1630-1635, 2020 07 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32544361
5.
Lot-to-lot consistency study of an Escherichia coli-produced bivalent human papillomavirus vaccine in adult women: a randomized trial.
Hum Vaccin Immunother
; 16(7): 1636-1644, 2020 07 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31770068